CSF
VictoryShares US Discovery Enhanced Volatility Wtd ETF
stock NASDAQ

$PSTV
HERE BOYS! Its official!
NCCN adding CSF - CT DNA. Obviously they cannot add the company names.
Guess who does CSF CT DNA testing? Just google it. Only one company! PLUS THERAPEUTICS!!

$PSTV – Legit sleeper biotech w/ real near-term catalysts
Trading under $1 and flying under the radar. Just filed to WITHDRAW their S-3 offering – which means no dilution for now. That alone is rare in this market (IXHL anyone?). Here’s why I’m watching:
✔️ They specialize in targeted radiotherapeutics for rare, aggressive cancers – like glioblastoma (GBM) and leptomeningeal metastases (LM). Big unmet needs.
✔️ Lead candidate Rhenium-186 is in Phase 1/2 trials for multiple indications and has Orphan Drug + Fast Track designation.
✔️ Key upcoming catalyst: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) Phase 1 data to be presented at SNO/ASCO on August 15, 2025. Phase 2 trial initiation planned. 3
✔️ Key upcoming catalyst 2 : CNSide - (FORESEE) Presentation due at SNO/ASCO CNS on August 14, 2025. Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted August 13, 2024. Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.
✔️ Recently granted FDA Rare Pediatric Disease Designation for LM – this opens up eligibility for a priority review voucher, worth $$$ if granted.
✔️ Clean cap table for now – no recent dilution, and they pulled the S-3. Either they’re confident in data or another non-dilutive funding route is coming.
✔️ Plus Therapeutics has restructured its $15 million equity financing to eliminate potential dilution of up to 1.5 billion shares.
✔️ Market cap is under $35M. One good PR and this thing could fly, like we’ve seen happen with other sub-$1 biotechs recently.
Target: 1.8–4$ short-term if data is clean.

$PSTV – Legit sleeper biotech w/ real near-term catalysts
Trading under $1 and flying under the radar. Just filed to WITHDRAW their S-3 offering – which means no dilution for now. That alone is rare in this market. Here’s why I’m watching:
✔️ They specialize in targeted radiotherapeutics for rare, aggressive cancers – like glioblastoma (GBM) and leptomeningeal metastases (LM). Big unmet needs.
✔️ Lead candidate Rhenium-186 is in Phase 1/2 trials for multiple indications and has Orphan Drug + Fast Track designation.
✔️ Key upcoming catalyst: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) Phase 1 data to be presented at SNO/ASCO on August 15, 2025. Phase 2 trial initiation planned. CNSide - (FORESEE) Presentation due at SNO/ASCO CNS on August 14, 2025. Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted August 13, 2024. Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.
✔️ Recently granted FDA Rare Pediatric Disease Designation for LM – this opens up eligibility for a priority review voucher, worth $$$ if granted.
✔️ Clean cap table for now – no recent dilution, and they pulled the S-3. Either they’re confident in data or another non-dilutive funding route is coming.
✔️ Plus Therapeutics has restructured its $15 million equity financing to eliminate potential dilution of up to 1.5 billion shares.
✔️ Market cap is under $15M. One good PR and this thing could fly, like we’ve seen happen with other sub-$1 biotechs recently.
Target: 1.8–4 short-term if data is clean.

$PSTV
HERE BOYS! Its official!
NCCN adding CSF - CT DNA. Obviously they cannot add the company names.
Guess who does CSF CT DNA testing? Just google it. Only one company! PLUS THERAPEUTICS!!

$PSTV – Legit sleeper biotech w/ real near-term catalysts
Trading under $1 and flying under the radar. Just filed to WITHDRAW their S-3 offering – which means no dilution for now. That alone is rare in this market (IXHL anyone?). Here’s why I’m watching:
✔️ They specialize in targeted radiotherapeutics for rare, aggressive cancers – like glioblastoma (GBM) and leptomeningeal metastases (LM). Big unmet needs.
✔️ Lead candidate Rhenium-186 is in Phase 1/2 trials for multiple indications and has Orphan Drug + Fast Track designation.
✔️ Key upcoming catalyst: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) Phase 1 data to be presented at SNO/ASCO on August 15, 2025. Phase 2 trial initiation planned. 3
✔️ Key upcoming catalyst 2 : CNSide - (FORESEE) Presentation due at SNO/ASCO CNS on August 14, 2025. Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted August 13, 2024. Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.
✔️ Recently granted FDA Rare Pediatric Disease Designation for LM – this opens up eligibility for a priority review voucher, worth $$$ if granted.
✔️ Clean cap table for now – no recent dilution, and they pulled the S-3. Either they’re confident in data or another non-dilutive funding route is coming.
✔️ Plus Therapeutics has restructured its $15 million equity financing to eliminate potential dilution of up to 1.5 billion shares.
✔️ Market cap is under $35M. One good PR and this thing could fly, like we’ve seen happen with other sub-$1 biotechs recently.
Target: 1.8–4$ short-term if data is clean.

$PSTV – Legit sleeper biotech w/ real near-term catalysts
Trading under $1 and flying under the radar. Just filed to WITHDRAW their S-3 offering – which means no dilution for now. That alone is rare in this market. Here’s why I’m watching:
✔️ They specialize in targeted radiotherapeutics for rare, aggressive cancers – like glioblastoma (GBM) and leptomeningeal metastases (LM). Big unmet needs.
✔️ Lead candidate Rhenium-186 is in Phase 1/2 trials for multiple indications and has Orphan Drug + Fast Track designation.
✔️ Key upcoming catalyst: REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM) Phase 1 data to be presented at SNO/ASCO on August 15, 2025. Phase 2 trial initiation planned. CNSide - (FORESEE) Presentation due at SNO/ASCO CNS on August 14, 2025. Trial data reported that the trial achieved its primary endpoint, demonstrating that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target, noted August 13, 2024. Additional trial data demonstrated enhanced sensitivity in detecting tumor cells (80%) vs. CSF cytology (29%) in patients with LM, noted November 22, 2024.
✔️ Recently granted FDA Rare Pediatric Disease Designation for LM – this opens up eligibility for a priority review voucher, worth $$$ if granted.
✔️ Clean cap table for now – no recent dilution, and they pulled the S-3. Either they’re confident in data or another non-dilutive funding route is coming.
✔️ Plus Therapeutics has restructured its $15 million equity financing to eliminate potential dilution of up to 1.5 billion shares.
✔️ Market cap is under $15M. One good PR and this thing could fly, like we’ve seen happen with other sub-$1 biotechs recently.
Target: 1.8–4 short-term if data is clean.